


Attachment to Page No 5

Page 1 of 5

| | | |
|--|---------------------------------|-------------------------------|
| FORM PTO 1449 INFORMATION DISCLOSURE STATEMENT  | ATTY. DOCKET NO. 0125-0016D3 | APPLICATION NO. 09/939,754 |
| | APPLICANT(S) McTigue et al. | |
| | FILING DATE August 28, 2001 | GROUP 1631 |

RECEIVED
OCT 03 2001
TECH CENTER 1601/2900

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|-----|--------------------|----------|--------------------|----------------|----------------|-------------|
| <i>[initials]</i> | AA1 | 4,966,849 | 10/30/90 | Valee et al. | 435 | 199 | |
| | AB1 | 5,217,999 | 6/8/93 | Levitzki, et. al. | 514 | 613 | |
| | AC1 | 5,302,606 | 4/12/94 | Spada et al. | 514 | 357 | |
| | AD1 | 5,330,992 | 7/19/94 | Eissenstat, et. al | 514 | 312 | |


FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|-----|--------------------|---------|---------|-------|-----------|---|
| <i>[initials]</i> | AE1 | WO91/15495 | 1991 | WO | — | — | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| | AF1 | WO92/20642 | 1992 | WO | — | — | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| | AG1 | WO92/21660 | 1992 | WO | — | — | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| | AH1 | WO94/03427 | 1991 | WO | — | — | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| | AI1 | WO94/10202 | 1994 | WO | — | — | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| | AJ1 | WO 98/49300 | 11/5/98 | WO | — | — | <input type="checkbox"/> Yes <input type="checkbox"/> No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|-------------------|----|----------|--|
| <i>[initials]</i> | AK | <u>1</u> | Adamis et al., <u>Arch. Ophthalmol.</u> , 114:66-71 (1996). |
| | AL | <u>1</u> | Agouron Pharmaceuticals, Inc. "Agouron Solves Structure of Key Target for Drugs to Block Angiogenesis: Human VEGF Receptor 2 Kinase", March 4, 1999. |
| | AM | <u>1</u> | Bazenet et al., <u>Mol. Cell. Biol.</u> , 16:6926-6936 (1996) |
| | AN | <u>1</u> | Borgström et al, <u>Cancer Res.</u> , 56:4032-4039 (1996) |
| | AO | <u>1</u> | Bourne, H.R., et al., <u>Basic & Clinical Pharmacology</u> , 3 rd Edition (Katzung et al., eds), Chapter 3, pages 9-22 (1987) |
| | AP | <u>1</u> | Choudhury et al., <u>FEBS Letters</u> , 282(2):351-354 (May, 1991) |
| | AQ | <u>1</u> | Dvorak et al., <u>Am. J. Path.</u> , 146:1029-1039 (1995) |
| | AR | <u>1</u> | DeVries et al., <u>Science</u> , 255:989-991 (1992) |
| | AS | <u>1</u> | Dougher-Vermazen et al., <u>Biochem. Biophys. Res. Comm.</u> , 205:728-738 (1994) |

| | |
|--|----------------------------|
| EXAMINER <i>[signature]</i> | DATE CONSIDERED 6-28-03 |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. | |

| | | | |
|---|--|---------------------------------|-------------------------------|
| FORM PTO 1449 | | ATTY. DOCKET NO. 0125-0016D3 | APPLICATION NO. 09/939,754 |
| INFORMATION DISCLOSURE STATEMENT  | | APPLICANT(S) McTigue et al. | |
| | | FILING DATE August 28, 2001 | GROUP 1631 |

RECEIVED
 OCT 03 2001
 TECH CENTER 1600/2905


U.S. PATENT DOCUMENTS


| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|--------------------|------|------|-------|-----------|-------------|
| | AA2 | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|--------------------|------|---------|-------|-----------|-------------|
| | AB2 | | | — | — | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|---|----|----------|---|
|  | AC | <u>2</u> | Ferrara & Henzel, <u>Biochem. Biophys. Res. Comm.</u> , 161:851-858 (1989) – Abstract only. |
| | AD | <u>2</u> | Ferrara N. and Davis-Smyth, <u>Endocrine Rev.</u> , 18:4-25 (1997) |
| | AE | <u>2</u> | Folkham, J. Natl., <u>Cancer Inst.</u> , 82:4-6 (1991) |
| | AF | <u>2</u> | Folkman et al., <u>J. Biol. Chem.</u> , 267:10931-10934 (1992) |
| | AG | <u>2</u> | Heidaran et al., <u>Mol. Cell. Biol.</u> , 11:134-142 (1991) |
| | AH | <u>2</u> | Hori et al., <u>Cancer Res.</u> , 51:6180-9184 (1991) |
| | AI | <u>2</u> | Houck, et al., <u>J. Biol. Chem.</u> , 267:26031-26037 (1992) |
| | AJ | <u>2</u> | Hubbard, <u>EMBO J.</u> , 16:5572-5581 (FGFR1) (1997) |
| | AK | <u>2</u> | Hubbard, et al., <u>Nature</u> , 372:746-754 (1994) |
| | AL | <u>2</u> | Jellinek, et al., <u>Biochemistry</u> , 3:10450-56 (1994) |
| | AM | <u>2</u> | Johnson et al., <u>Cell</u> , 85:149-158 (1996) |
| | AN | <u>2</u> | Kazlauskas et al., <u>Mol. Cell. Biol.</u> , 12:2534-2544 (1992) |
| | AO | <u>2</u> | Kim et al., <u>Nature</u> , 362:841-843 (1993) |
| | AP | <u>2</u> | Kinsella, et al., <u>Exp. Cell Res.</u> , 199:56-62 (1992) |
| | AQ | <u>2</u> | Klagsburn & Soker, <u>Current Biology</u> , 3:699-702 (1993) |
| | AR | <u>2</u> | Knighton et al., <u>Science</u> , 253:407-413 (1991) |
| ✓ | AS | <u>2</u> | Kumar and Fidler, <u>In Vivo</u> , 18:27-34 (1998) – Abstract only. |

| | |
|--|----------------------------|
| EXAMINER  | DATE CONSIDERED 6-25-03 |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. | |

TECH CENTER 1600/2900

OCT 03 2001


RECEIVED


| | | | |
|----------------------------------|--|---------------------------------|-------------------------------|
| FORM PTO 1449 | | ATTY. DOCKET NO. 0125-0016D3 | APPLICATION NO. 09/939,754 |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S) McTigue et al. | |
| | | FILING DATE August 28, 2001 | GROUP 1631 |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|-----|--------------------|------|------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
| | AA3 | | | | | | |


| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-----|--------------------|------|---------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
| | AB3 | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|---|----|----------|---|
|  | AC | <u>3</u> | Lev et al., <u>Proc. Natl. Acad. Sci. USA</u> , 89:678-682 (1992) |
| | AD | <u>3</u> | Matsui, T., et al., <u>Science</u> , 243:800-804 (1989) |
| | AE | <u>3</u> | McLeskey et al., <u>Cancer Res.</u> , 53:2168-2177 (1993) |
| | AF | <u>3</u> | McRee et al., <u>J. Struct. Biol.</u> , 125 (2-3):156-165 (1999) – Abstract only. |
| | AG | <u>3</u> | Mohammadi et al., <u>Cell</u> , 86:577-87 (1996) |
| | AH | <u>3</u> | Mohammadi et al., <u>Science</u> , 276:955-960 (1997) |
| | AI | <u>3</u> | Mullis, et al. <u>Biotechnology</u> , 24:17-27 (1992) – Abstract Only. |
| | AJ | <u>3</u> | Parast et al., <u>Biochemistry</u> , 37(47):16788-16801 (11/05/1998) |
| | AK | <u>3</u> | Pepper, M.S., <u>Vasc. Med.</u> , 1:259-266 (1996) – Abstract Only. |
| | AL | <u>3</u> | Reedjik, et al., <u>EMBO J.</u> , 11:1365-1372 (1992) |
| | AM | <u>3</u> | Risau, W., <u>FASEB J.</u> , 9:926-933 (1995) |
| | AN | <u>3</u> | Schuchter, et al., <u>Cancer Res.</u> , 51:682-687 (1991) |
| | AO | <u>3</u> | Seetharm, et al., <u>Oncogene</u> , 10:135-147 (1995) |
| | AP | <u>3</u> | Severinsson et al., <u>Mol. Cell. Biol.</u> , 10:801-809 (1990) |
| | AQ | <u>3</u> | Shalaby et al., <u>Nature</u> , 376:576-579 (1995) |
| | AR | <u>3</u> | Shibuya, et al., <u>Oncogene</u> , 5:519-524 (1990) |
| | AS | <u>3</u> | Szekanecz, et al., <u>J. Investig. Med.</u> , 46:27-41 (1998) |

| | |
|---|----------------------------|
| EXAMINER  | DATE CONSIDERED 6-25-03 |
|---|----------------------------|



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | |
|---|--|---------------------------------|-------------------------------|
| FORM PTO 1449 | | ATTY. DOCKET NO. 0125-0016D3 | APPLICATION NO. 09/939,754 |
| INFORMATION DISCLOSURE STATEMENT  | | APPLICANT(S) McTigue et al. | |
| | | FILING DATE August 28, 2001 | GROUP 1631 |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|-----|-----------------|------|------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
| | AA4 | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-----|-----------------|------|---------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
| | AB4 | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


| | | | |
|---|----|----------|--|
|  | AC | <u>4</u> | Takano, et al., <u>Mol. Bio. Cell</u> , 4:358A, (1993) |
| | AD | <u>4</u> | Taylor, et al., <u>EMBO Journal</u> , 8(7):2029-2037 (1989) |
| | AE | <u>4</u> | Terman et al., <u>Biochem Biophys. Res. Commun.</u> , 187:1579-8 (1992) |
| | AF | <u>4</u> | Thomas, K., <u>J. Biol Chem</u> , 271(2):603-606 (1996) – Abstract only. |
| | AG | <u>4</u> | Thomas & Kendall, <u>Proc. Natl. Acad. Sci.</u> , 90:10705-09, (1994) |
| | AH | <u>4</u> | Tolentino and Adamis, <u>Int. Ophthalmol. Clin.</u> 38:77-94, (1988) |
| | AI | <u>4</u> | Vaisman et al., <u>J. Biol. Chem.</u> , 265:19461-19566, (1990) |
| | AJ | <u>4</u> | van der Geer et al., <u>Ann. Rev. Cell Biol</u> , 10:251-337, (1994) – Abstract only. |
| | AK | <u>4</u> | Waltenberger et al., <u>J. Biol. Chem.</u> , 269:26988-26995, (1994) |
| | AL | <u>4</u> | Wei et al., <u>J. Biol. Chem.</u> , 270:8122-8130, (1995) |
| | AM | <u>4</u> | Weidner, et al., <u>New Engl. J. Med.</u> , 324:1-5, (1991) |
| | AN | <u>4</u> | Yamaguchi and Hendrickson, <u>Nature</u> , 384:484-489 (1996) |
| | AO | <u>4</u> | Yu et al., <u>Mol. Cell. Biol.</u> , 11:3780-3785 (1991) |
| | AP | <u>4</u> | McTigue, et al. "Crystal Structure of the Kinase Domain of Human Vascular Endothelial Growth Factor Receptor 2: A Key Enzyme in Angiogenesis," <u>Structure</u> 1999; 7:319-330 |
| | AQ | <u>4</u> | Al-Obeidi, et al., "Protein Tyrosine Kinases: Structure, Substrate Specificity, and Drug Discovery," <u>Biopolymers (Peptide Science)</u> , Vol. 47, 197-223 (1998). |
| | AR | <u>4</u> | Wei, et al., "Expression, Characterization, and Crystallization of the Catalytic Core of the Human Insulin Receptor Protein-tyrosine Kinase Domain," <u>J. Biol. Chem.</u> 1995; 270(14): 8122-8130. |
|  | AS | <u>4</u> | Hubbard, et al., "Crystal Structure of the Tyrosine Kinase Domain of the Human Insulin Receptor," <u>Nature</u> 1994; 372:746-759. |

EXAMINER

DATE CONSIDERED

6-25-05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | |
|---|--|---------------------------------|-------------------------------|
| FORM PTO 1449 INFORMATION DISCLOSURE STATEMENT | | ATTY. DOCKET NO. 0125-0016D3 | APPLICATION NO. 09/939,754 |
|  | | APPLICANT(S) McTigue et al. | |
| | | FILING DATE August 28, 2001 | GROUP 1631 |

RECEIVED
 OCT 08 2001
 TECH CENTER 160012909


U.S. PATENT DOCUMENTS


| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|--------------------|------|------|-------|-----------|-------------|
| | AA5 | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|--------------------|------|---------|-------|-----------|-------------|
| | AB5 | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|----------|--|
|  | AC | <u>5</u> | SCOPES, "Protein Purification: Principles and Practice," Second Ed., 1987, pp. 297-301. |
| | AD | <u>5</u> | Mohammadi, et al., "Structure of the Tyrosine Kinase Domain of Fibroblast Growth Receptor in Complex with Inhibitors," Science 997; 276: 955-960. |
| | AE | <u>5</u> | McDonald, et al., "The First Structure of a Receptor Tyrosine Kinase Domain: A Further Step in Understanding the Molecular Basis of Insulin Action," Structure 1995; 3:1-6. |
| | AF | <u>5</u> | Singh, et al., Structure-Based Design of a Potent, Selective, and Irreversible Inhibitor of the Catalytic Domain of the erbB Receptor Subfamily of Protein Tyrosine Kinases," J. Med. Chem. 1997; 40: 1130-1135. |
| | AG | <u>5</u> | |
| | AH | <u>5</u> | |
| | AI | <u>5</u> | |
| | AS | <u>5</u> | |

| | |
|---|-------------------------|
| EXAMINER  | DATE CONSIDERED 6-25-03 |
| EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. | |